Telix already controls roughly 60% of the U.S. PSMA-PET market through Illuccix and Gozellix, and that dominance means the real commercial ceiling isn’t in selling more scans — it’s in owning the workflows those scans enable. The simultaneous letters of intent with EDAP TMS and Profound Medical are not a research gesture; they are a deliberate attempt to embed Telix’s imaging agents as the default diagnostic layer inside two growing minimally invasive treatment platforms before those platforms scale.
The logic is straightforward. HIFU via EDAP’s Focal One and MRI-guided TULSA via Profound’s TULSA-PRO are both gaining ground as alternatives to surgery and radiation precisely because they minimize incontinence and erectile dysfunction. But their clinical weak spot is patient selection and post-treatment surveillance — exactly where PSMA-PET adds the most value. If Telix can generate evidence that links its agents to superior treatment planning and recurrence monitoring in focal and whole-gland ablation, then urologists adopting these platforms face a practical pull toward Gozellix or Illuccix. The imaging agent becomes part of the procedure’s infrastructure, not a separate ordering decision.
Telix also manages a competitive timing risk here. Lantheus’s PYLARIFY and point-of-care F-18 agents are structurally better positioned for high-volume hospital systems, and any platform that standardizes around a competitor’s agent locks Telix out of that workflow for years. Securing early collaboration agreements with EDAP — which has a growing global installed Focal One base — and Profound, which holds FDA clearance and multi-market approvals, forecloses that possibility before it becomes a problem. Letters of intent are non-binding, but the evidence generation they initiate creates institutional inertia that binding contracts rarely replicate.
The critical variable to track is whether these collaborations produce peer-reviewed outcome data within 18 months. Evidence generation is the stated purpose, but evidence publication is what converts a partnership into a prescribing norm. Without published data linking PSMA-PET guidance to measurable improvements in focal therapy outcomes — recurrence rates, margin status, functional preservation — this stays a marketing arrangement dressed in scientific language. The moment a prospective study reports a PSA progression benefit in PSMA-guided TULSA or HIFU, Telix’s reimbursement argument to payers for pre-procedural imaging becomes categorically harder to deny.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
